Pharmacopsychiatry Journal

???? Celebrating International Women's Day! ???? This #InternationalWomensDay, all of us at Pharmacopsychiatry celebrate the pivotal contributions of all women in #STEM. We are committed to equity in research and innovation. To our editors, our authors, our readers, and our community - we appreciate you. #WomenInScience #GirlsInSTEM #WomenInSTEM #STEMforAll #ScienceForAll #InclusiveScience #InspireTheFuture

?? An excellent #Review to read this #weekend! Systematic Review and Meta-Analysis of L-Methylfolate Augmentation in Depressive Disorders ? by Abdullah M., Ethan Poweleit, Lisa C. Brown, PhD, Jeffrey Strawn, and Chad Bousman ?? Almost one in five people experience one episode of major depressive disorder (MDD) at some point in their life that severely impacts #psychosocial functioning and diminishes their quality of life. ? ?? Partial response to #pharmacotherapy is common in MDD and many patients require alternative pharmacotherapy or augmentation, including adjunctive L-methylfolate. ? ?? Given that L-methylfolate augmentation is rarely included in major clinical practice guidelines, this Review sought to systematically review evidence for L-methylfolate augmentation in adults with MDD and to examine its efficacy meta-analytically. ? ??Read the full article on: https://lnkd.in/duVE7ep5 ? #MentalHealth #MajorDepressiveDisorder

?? A fascinating #OpenAccess?read for your #weekend! Twenty-Three Years of Declining Lithium Use: Analysis of a Pharmacoepidemiological Dataset from German-Speaking Countries ? by Waldemar Greil, Mateo de Bardeci, Nadja Nievergelt, Sermin Toto, Renate Grohmann, Johanna Seifert, and Georgios Schoretsanitis ? ?? #Pharmacoepidemiological data suggest that #lithium prescriptions for #bipolar disorder are gradually decreasing, with less attention having been paid to other indications. ? ?? Lithium’s main #psychotropic co-medications were #quetiapine, #lorazepam, and #olanzapine. ?? In inpatients, the use of lithium has decreased in patients with bipolar disorder and also with various other #psychiatric diagnoses. ? ??Read the full article on our website today: https://lnkd.in/endEtNwk ? #MentalHealth

A great #OpenAccess Review for you to read this weekend: Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature by Kirsten Müller-Vahl ?? Although an increasing number of patients suffering from mental illnesses self-medicate with?#cannabis, current knowledge about the efficacy and safety of?cannabis-based medicine in #psychiatry is still extremely limited. ?? This Review looks into the current literature and summarizes research into cannabis-based #medicines and their potential for use in the #treatment of #psychiatric disorders, such as CUD, autism spectrum disorder (ASD), Tourette syndrome (TS), PTSD, anxiety disorders, sleeping disorders, ADHD, and depression. ?? Read the full article online to find out more: https://lnkd.in/gV7QvfRD

?? An?#OpenAccess?read for your #weekend! Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study ? by Dr. Xenia M. Hart, Friederike Amann,?Jonas Brand, Luzie Eichentopf, and Gerhard Gründer ? ?? This retrospective study examines the treatment effects of Escitalopram (also known as Lexapro or Cipralex) and pharmacokinetic influences on blood levels. ? ?? The sample data comprised 134 patients aged from 14 to 89 years, most of which were diagnosed with #depression. ?? The findings strongly support the recommended threshold of 15 ng/mL for the antidepressant efficacy of escitalopram and emphasize the need for therapeutic drug monitoring (TDM) to support decisions on dosing in individuals. ? ??Read the full article today: https://lnkd.in/dp7r2bSB #MentalHealth

???? Celebrating Women in Science! ???? Science thrives on #diversity and #collaboration and today, on the International Day of Women and Girls in Science, all of us at Pharmacopsychiatry celebrate the brilliant minds shaping the future of discovery, innovation, and progress in #pharmacological #psychiatric #research. ?? ?? ? From pioneering research to groundbreaking advancements, women in #STEM are making history every day. Let’s celebrate their achievements, amplify their voices, and inspire the next generation of young scientists! ?????? #WomenInScience #GirlsInSTEM #WomenInSTEM #STEMforAll #ScienceForAll #InclusiveScience #InspireTheFuture #PsychiatryResearch #Psychiatry

?? A great Pharmacopsychiatry Monday read: Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point by Florian Holsboer and?Marcus Ising (Max Planck Institute of Psychiatry) Head to our website to find out all about their #precision #medicine approach looking for the next major innovation in the #pharmacotherapy of #depression. ?? https://lnkd.in/d9s27f-Y

?? A great weekend read from Pharmacopsychiatry today: "ABC Family Gene Polymorphisms and Cognitive Functions Interact to Influence Antidepressant Efficacy" by Meijiang Jin,?Lei Ji,?Maojia Ran,?Zhujun Wang,?Yan Bi,?Hang Zhang,?Yuanmei Tao,?Hanmei Xu,Shoukang Zou,?Hong Zhang,?Tao Yu,?Li Yin (West China Hospital of Sichuan University, Chengdu) ?? The importance of identifying relevant indicators of #antidepressant efficacy is highlighted by the low response rates to antidepressant #treatment for depression. The ABC gene family, encoding ATP-dependent transport proteins facilitating the transport of #psychotropic drugs, has drawn attention. This study delved into the relationship between antidepressant efficacy and seven single nucleotide polymorphisms of ABCB1 and ABCB6 genes. ?? Read the full article on our website: https://lnkd.in/d3cGyDgy

?? Pharmacopsychiatry is now on LinkedIn! ?? Pharmacopsychiatry?is a Thieme International Science journal that provides #psychiatrists, #neuroscientists and #clinicians?with key clinical insights and describes new avenues of research and treatment. The pharmacological and?neurobiological bases of #PsychiatricDisorders are?discussed by presenting clinical and experimental research. ?? Pharmacopsychiatry is a Q1 #psychiatry journal led by Editor-in-Chief Prof. Michael Bauer (Univ. Dresden) and is the official journal partner of the AGNP (https://agnp.de/). ?? Check out our website for more details: https://lnkd.in/dKzmxptd